Proteomic analysis reveals that pheophorbide a-mediated photodynamic treatment inhibits prostate cancer growth by hampering GDP-GTP exchange of ras-family proteins

Photodynamic treatment (PDT) is a promising modality in delivering focused treatment in primary and post-radiotherapy prostate cancer patients. It aims to eradicate cancer lesion but minimise damage to adjacent structures and hence helps in the preservation of urinary, sexual, and bowel functions [1]. PDT involves activation of a photosensitizer (PS) by light of a specific wavelength, generating transient levels of reactive oxygen species (ROS). PSs that have been studied, mainly include hematoporphyrin derivatives (Photofrin), aminolevulinic acid (5-ALA), verteporfin (visudyne), and chlorophyll derivatives (pheophorbide a, PhA, the photosensitizer used in this study) [2].

Source: Photodiagnosis and Photodynamic Therapy - May 22, 2018 Category: Laser Surgery Authors: Dan Dan Xu, Chong Bing Xu, Hon Ming Lam, Fuk-Ling Wong, Albert Wing Nang Leung, Merrin Man Long Leong, William Chi Shing Cho, Robin Hoeven, Lv Qing Tao, Rong Rong Source Type: research